Oric Pharmaceuticals Stock Based Compensation History

Name: Oric Pharmaceuticals Stock Based Compensation Historical Data
Creator: Macroaxis
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Stock Based Compensation Stock ORIC Oric Pharmaceuticals

ORIC Stock

USD 11.70 0.60 5.41%

Stock Based Compensation is currently 26.3 M, compared with 25 M a year ago. Its Stock Based Compensation has been strengthening recently. View All Financial Accounts

Stock Based Compensation

First Reported

2019-03-31

Previous Quarter

5.6 M

Current Value

6.3 M

Quarterly Volatility

2 M

Macro event markers

Covid

Interest Hikes

Oric Pharmaceuticals reports Stock Based Compensation as part of its standard financial disclosures each period.

Latest Oric Pharmaceuticals' Stock Based Compensation Growth Pattern

The historical Stock Based Compensation for Oric Pharmaceuticals spanning 9 fiscal years is laid out below. Sustained strengthening momentum across multiple periods strengthens confidence in the directional signal. Where the latest reading sits relative to the full range often matters more than the absolute level. The distance between recent values and long-run averages may signal mean-reversion potential. Comparing different time windows of Oric Pharmaceuticals' Stock Based Compensation can reveal whether the pace of change is accelerating or slowing.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Stock Based Compensation Trend Statistics

	Arithmetic Mean	7,112,976
	Geometric Mean	55,855
	Coefficient Of Variation	136.21
	Mean Deviation	8,400,000
	Median	469,000
	Standard Deviation	9,688,303
	Sample Variance	93.9T
	Range	26.3M
	R-Value	0.88
	Mean Square Error	22.1T
	R-Squared	0.78
	Slope	1,693,674
	Total Sum of Squares	1501.8T

Oric Pharmaceuticals Stock Based Compensation History

	2026	26.3 M
	2025	25 M
	2024	20.2 M
	2023	15.2 M
	2022	14.5 M
	2021	12.9 M
	2020	5.3 M
	2019	1.1 M
	2018	469 K

Other Related Fundamentals

Stock Based Compensation To Revenue

Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Capital Surpluse	Net Invested Capital	Net Working Capital	Deferred Long Term Liab	Short Term Debt	Short Term Investments
Total Assets		0.98	0.95	0.97	-0.41	-0.85	0.63	0.2	0.98	0.85	0.21	0.97	0.99	0.98	-0.96	0.85	-0.4
Total Stockholder Equity	0.98		0.93	0.93	-0.4	-0.81	0.62	0.0	0.96	0.82	0.22	0.95	0.98	0.97	-0.94	0.81	-0.38
Net Tangible Assets	0.95	0.93		0.88	-0.4	-0.82	0.63	0.15	0.96	0.82	0.15	0.95	0.94	0.97	-0.99	0.81	-0.49
Current Deferred Revenue	0.97	0.93	0.88		-0.41	-0.83	0.54	0.29	0.96	0.82	0.17	0.93	0.98	0.94	-0.91	0.83	-0.36
Net Debt	-0.41	-0.4	-0.4	-0.41		0.07	-0.06	-0.1	-0.43	-0.09	0.48	-0.36	-0.44	-0.42	0.38	-0.15	0.85
Retained Earnings	-0.85	-0.81	-0.82	-0.83	0.07		-0.82	-0.23	-0.81	-0.98	-0.49	-0.83	-0.84	-0.81	0.85	-0.94	0.18
Accounts Payable	0.63	0.62	0.63	0.54	-0.06	-0.82		0.05	0.54	0.87	0.45	0.55	0.6	0.57	-0.6	0.67	-0.17
Total Liab	0.2	0.0	0.15	0.29	-0.1	-0.23	0.05		0.19	0.18	-0.02	0.2	0.15	0.15	-0.19	0.25	-0.12
Total Current Assets	0.98	0.96	0.96	0.96	-0.43	-0.81	0.54	0.19		0.81	0.1	0.96	0.99	1.0	-0.97	0.8	-0.39
Common Stock	0.85	0.82	0.82	0.82	-0.09	-0.98	0.87	0.18	0.81		0.4	0.8	0.85	0.82	-0.84	0.87	-0.16
Property Plant Equipment	0.21	0.22	0.15	0.17	0.48	-0.49	0.45	-0.02	0.1	0.4		0.31	0.15	0.09	-0.2	0.6	0.18
Capital Surpluse	0.97	0.95	0.95	0.93	-0.36	-0.83	0.55	0.2	0.96	0.8	0.31		0.95	0.95	-0.97	0.9	-0.45
Net Invested Capital	0.99	0.98	0.94	0.98	-0.44	-0.84	0.6	0.15	0.99	0.85	0.15	0.95		0.98	-0.95	0.82	-0.4
Net Working Capital	0.98	0.97	0.97	0.94	-0.42	-0.81	0.57	0.15	1.0	0.82	0.09	0.95	0.98		-0.97	0.78	-0.38
Deferred Long Term Liab	-0.96	-0.94	-0.99	-0.91	0.38	0.85	-0.6	-0.19	-0.97	-0.84	-0.2	-0.97	-0.95	-0.97		-0.86	0.47
Short Term Debt	0.85	0.81	0.81	0.83	-0.15	-0.94	0.67	0.25	0.8	0.87	0.6	0.9	0.82	0.78	-0.86		-0.33
Short Term Investments	-0.4	-0.38	-0.49	-0.36	0.85	0.18	-0.17	-0.12	-0.39	-0.16	0.18	-0.45	-0.4	-0.38	0.47	-0.33

Click cells to compare fundamentals

Related Accounts

		Last Reported	End Of Year Estimate
	Stock Based Compensation	25 M	26.3 M

Methodology, Assumptions & Data Sources

Below is Oric Pharmaceuticals's Stock Based Compensation history. A strong fit to a straight line suggests the trend is dependable.

Data shown for Oric Pharmaceuticals is aggregated from periodic company reporting and market reference feeds and normalized across reporting formats. Analyst inputs may be included when coverage is available. Source publication timing can introduce delays. This section presents reference data and historical patterns only and does not constitute an investment recommendation or advice.

This content is curated and reviewed by:

Michael Smolkin - Member of Macroaxis Board of Directors

Last reviewed on March 20th, 2026

Macroaxis provides analytical tools and reference data for investors of all levels to evaluate holdings and assess risk across market volatility, economic shifts, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Oric Pharmaceuticals Stock Based Compensation History

Latest Oric Pharmaceuticals' Stock Based Compensation Growth Pattern

Stock Based Compensation Trend Statistics

Oric Pharmaceuticals Stock Based Compensation History

Other Related Fundamentals

Stock Based Compensation component correlations

Related Accounts

Methodology, Assumptions & Data Sources

This content is curated and reviewed by:

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY